174 related articles for article (PubMed ID: 17108145)
21. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.
Buck AK; Kratochwil C; Glatting G; Juweid M; Bommer M; Tepsic D; Vogg AT; Mattfeldt T; Neumaier B; Möller P; Reske SN
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1775-82. PubMed ID: 17541585
[TBL] [Abstract][Full Text] [Related]
22. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
23. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
[TBL] [Abstract][Full Text] [Related]
24. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000
[TBL] [Abstract][Full Text] [Related]
25. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
27. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.
Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U
J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875
[TBL] [Abstract][Full Text] [Related]
28. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors.
Herrmann K; Eckel F; Schmidt S; Scheidhauer K; Krause BJ; Kleeff J; Schuster T; Wester HJ; Friess H; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2008 Sep; 49(9):1437-44. PubMed ID: 18703612
[TBL] [Abstract][Full Text] [Related]
29. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
[TBL] [Abstract][Full Text] [Related]
30. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
[TBL] [Abstract][Full Text] [Related]
31. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
[TBL] [Abstract][Full Text] [Related]
32. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.
Kasper B; Egerer G; Gronkowski M; Haufe S; Lehnert T; Eisenhut M; Mechtersheimer G; Ho AD; Haberkorn U
Leuk Lymphoma; 2007 Apr; 48(4):746-53. PubMed ID: 17454633
[TBL] [Abstract][Full Text] [Related]
33. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
[TBL] [Abstract][Full Text] [Related]
34. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
35. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
36. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
37. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
[TBL] [Abstract][Full Text] [Related]
38. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ
J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613
[TBL] [Abstract][Full Text] [Related]
39. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
40. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
